| Title |
Of mice and men: divergent risks of teriparatide-induced osteosarcoma
|
|---|---|
| Published in |
Osteoporosis International, July 2009
|
| DOI | 10.1007/s00198-009-1004-0 |
| Pubmed ID | |
| Authors |
V. Subbiah, V. S. Madsen, A. K. Raymond, R. S. Benjamin, J. A. Ludwig |
| Abstract |
Since approval by the U.S. Food and Drug Administration (FDA) in December 2002, teriparatide (recombinant 1-34 PTH; Forteo) has been safely used by more than 430,000 patients. Prior to FDA approval, however, there was concern that teriparatide might increase the risk for patients to develop osteosarcoma, as almost 45% of the rats treated with this drug at the highest-tested dose level developed this aggressive form of bone cancer. Balancing the proven benefits of teriparatide shown by clinical trials with the theoretical risk for teriparatide-induced human osteosarcoma, the FDA mandated both a 'black-box' warning of this potential side-effect and a company-sponsored postmarketing surveillance program. As a participating institute of that surveillance program, we report upon the second person with potential teriparatide-induced osteosarcoma, in this case, complicated by a history of pelvic radiation. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 85 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 83 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 19 | 22% |
| Researcher | 16 | 19% |
| Student > Master | 9 | 11% |
| Other | 7 | 8% |
| Student > Bachelor | 5 | 6% |
| Other | 16 | 19% |
| Unknown | 13 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 36 | 42% |
| Agricultural and Biological Sciences | 9 | 11% |
| Biochemistry, Genetics and Molecular Biology | 7 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Engineering | 3 | 4% |
| Other | 9 | 11% |
| Unknown | 17 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 August 2018.
All research outputs
#15,684,532
of 23,306,612 outputs
Outputs from Osteoporosis International
#2,430
of 3,698 outputs
Outputs of similar age
#94,694
of 111,425 outputs
Outputs of similar age from Osteoporosis International
#22
of 24 outputs
Altmetric has tracked 23,306,612 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,698 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 111,425 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.